Literature DB >> 9725475

Average parameters in bioavailability studies: an application to slow-release amitriptyline formulation.

P Fagiolino1, M Vázquez, E Savio, L Domínguez, J M Aiache, E Beyssac.   

Abstract

In order to assess the extent and the rate of absorption in bioavailability studies, area under the curve (AUC), experimental maximum concentration (Cmax) and experimental time to reach Cmax (Tmax), are used. But when slow-release formulations are considered, the drug concentration-time curves usually show multiple peaks, and it is difficult to compute a Cmax and Tmax value. In case a Cmax value is computed, important variability in this parameter results in high values in the residual variance of the ANOVA test. So in order to decrease the high variability, average parameters: average concentration (Cav), average maximum concentration (Cmax,av) and Cmax,av x 100/Cav (%Cmax,av), are proposed. These new parameters were applied in a bioavailability study of slow-release amitriptyline formulation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9725475     DOI: 10.1007/BF03189333

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  3 in total

Review 1.  Pharmacokinetic characterization of controlled-release formulations.

Authors:  V W Steinijans
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Apr-Jun       Impact factor: 2.441

Review 2.  Discrepancies between pharmacokinetic studies of amitriptyline.

Authors:  P Schulz; P Dick; T F Blaschke; L Hollister
Journal:  Clin Pharmacokinet       Date:  1985 May-Jun       Impact factor: 6.447

3.  Bioequivalence: performance of several measures of rate of absorption.

Authors:  F Y Bois; T N Tozer; W W Hauck; M L Chen; R Patnaik; R L Williams
Journal:  Pharm Res       Date:  1994-07       Impact factor: 4.200

  3 in total
  1 in total

1.  Physiologically based pharmacokinetic-quantitative systems toxicology and safety (PBPK-QSTS) modeling approach applied to predict the variability of amitriptyline pharmacokinetics and cardiac safety in populations and in individuals.

Authors:  Zofia Tylutki; Aleksander Mendyk; Sebastian Polak
Journal:  J Pharmacokinet Pharmacodyn       Date:  2018-06-25       Impact factor: 2.745

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.